Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528333 · ClinicalTrials.gov registry record · Phase 2
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
A Phase 2 study of Acute Myeloid Leukemia, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
- 20
- Study locations
NCT00528333: Completed Phase 2 study of Acute Myeloid Leukemia, sponsored by Seagen.
NCT00528333 is a Phase 2 study of Acute Myeloid Leukemia that has completed, run by Seagen. The registered enrollment target is 211 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00528333, a Phase 2 study of Acute Myeloid Leukemia, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lintuzumab (SGN-33)
- DRUG Low dose cytarabine
Study Locations (20)
California
- Tower Cancer Research Foundation - Beverly Hills
- Glendale Memorial Hospital - Glendale
- Kenmar Research Institute - Los Angeles
- University of California Los Angeles - Los Angeles
- Bay Area Cancer Research Group - Pleasant Hill
Florida
- Lakeland Regional Cancer Center - Lakeland
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Illinois
- Rush University Medical Center - Chicago
- Joliet Oncology-Hematology Associates - Joliet
New York
- Northshore University Hospital, Monter Cancer Center - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
Alabama
- Southern Cancer Center - Mobile
Colorado
- University of Colorado Cancer Center - Aurora
Michigan
- Michigan State University, Breslin Cancer Center - Lansing
Montana
- Billings Clinic Cancer Research - Billings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
What the finished NCT00528333 record still lists
NCT00528333 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (83% higher).
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00528333 names 20 study sites across 13 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00528333 about?
NCT00528333 is a clinical study titled "A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML". The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
What is the current status of trial NCT00528333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2007-09. Estimated completion is 2010-08.
What conditions does trial NCT00528333 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT00528333?
The interventions under investigation include: Placebo (DRUG), Lintuzumab (SGN-33) (DRUG), Low dose cytarabine (DRUG).
Who is sponsoring clinical trial NCT00528333?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00528333 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00528333's enrollment target sits among peer trials
211 43rd of 306 higher than 264 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia